AarogyaAI: A Healthtech Startup that Diagnoses Drug Resistance with AI and Genomics

AarogyaAI: A Healthtech Startup that Diagnoses Drug Resistance with AI and Genomics – Drug resistance is a serious threat to global health, especially for infectious diseases such as tuberculosis (TB), HIV, and COVID-19. Drug resistance occurs when bacteria, viruses, or fungi mutate and become resistant to the drugs that are used to treat them. This makes the infections harder to cure, more costly, and more likely to spread.

According to the World Health Organization (WHO), drug-resistant TB is responsible for about 1.4 million deaths every year, and is one of the leading causes of death from antimicrobial resistance (AMR). Drug-resistant HIV affects about 12.6 million people worldwide, and reduces the effectiveness of antiretroviral therapy (ART). Drug-resistant COVID-19 variants have emerged in different countries, and pose a challenge to the vaccine development and deployment.

The diagnosis of drug resistance is crucial for the effective treatment and prevention of these infections. However, the current methods of diagnosis are slow, expensive, and inaccurate. They rely on culturing the pathogens in the laboratory, which can take weeks or months, and testing their sensitivity to different drugs, which can be affected by human errors and environmental factors.

AarogyaAI

Details of the startup:

  • CITY: Bengaluru
  • STATE: Karnataka
  • STARTED IN: 2019
  • FOUNDERS:  Avlokita Tiwari and Praapti Jayaswal
  • NUMBER OF INVESTORS : 3
  • LATEST ROUND INVESTMENT : ₹52.00M
  • TOTAL INVESTMENT : ₹69.32M
  • TOTAL SECURED LOANS AVAILED :Nil

You can find their website here.

This is where AarogyaAI comes in. AarogyaAI is a healthtech startup that uses artificial intelligence (AI) and genomics to diagnose drug resistance in a fast, accurate, and affordable way. Founded in 2019 by Dr. Adarsh Natarajan,  Avlokita Tiwari and Praapti Jayaswal, AarogyaAI has developed a cloud-based software as a service (SaaS) platform that can analyse the DNA sequence of the pathogen and provide a comprehensive report of its drug susceptibility status within minutes.

Bristol Myers to Acquire RayzeBio for $4.1 Billion to Expand Cancer Drug Business

How does AarogyaAI work?

AarogyaAI works by using next-generation sequencing (NGS) technology, which can read the entire genome of the pathogen from a patient sample, such as sputum, blood, or saliva. The DNA sequence is then uploaded to AarogyaAI’s SaaS platform, where it is processed by a machine-learning algorithm that can detect the presence of known and novel mutations that confer drug resistance.

AarogyaAI’s algorithm is trained on global and local databases of drug-resistant pathogens, as well as extensive literature research. It can identify the mutations that are associated with resistance to different classes of drugs, such as first-line, second-line, and third-line drugs. It can also predict the resistance to new drugs that are not yet available in the market, such as bedaquiline and delamanid for TB.

AarogyaAI’s platform then generates a user-friendly report that shows the drug susceptibility profile of the pathogen, along with the confidence score, the mutation details, and the relevant references. The report can be accessed from any web browser and device, such as a website, mobile, or tablet app. The report can also be shared with the clinicians, who can use it to make data-driven treatment decisions and prescribe the most effective and personalized therapy for the patient.

OmiX Labs: Making Healthcare Accessible Through DNA Diagnostics

What are the benefits of AarogyaAI?

AarogyaAI offers several benefits for both the patients and the healthcare providers, such as:

  • Faster and accurate diagnosis: AarogyaAI can provide the results within minutes, compared to the conventional methods that can take weeks or months. AarogyaAI can also detect the resistance to multiple drugs, including the new and experimental ones, with high accuracy and reliability.
  • Lower cost and higher accessibility: AarogyaAI can reduce the cost of diagnosis by eliminating the need for culturing and testing the pathogens in the laboratory. AarogyaAI can also increase the accessibility of diagnosis by being compatible with any NGS technology and patient specimen, and by being available online and offline.
  • Better treatment and prevention: AarogyaAI can help the clinicians to prescribe the most effective and personalized therapy for the patient, which can improve the cure rate, reduce the side effects, and prevent the transmission of drug-resistant infections. AarogyaAI can also help the public health authorities to monitor and control the spread of drug resistance and design appropriate policies and interventions.
Oncophenomics: Demystifying Cancer with the Power of Big Data

What Customers Say About AarogyaAI

AarogyaAI has received positive feedback from its customers, who have experienced improved diagnosis and treatment outcomes for DR-TB patients. Here are some of the testimonials from AarogyaAI’s customers:

  • AarogyaAI is a game-changer for DR-TB diagnosis and treatment. It has helped us to reduce the time and cost of diagnosis, and to provide personalized and effective treatment to our patients. AarogyaAI is easy to use and integrates well with our workflow.” – Dr. Rajesh Kumar, Head of TB Department, Apollo Hospital
  • AarogyaAI is a powerful tool for DR-TB research and innovation. It has enabled us to analyse the genomic data of TB bacteria from different regions and populations, and to discover new patterns and insights into the evolution and transmission of drug resistance. AarogyaAI is a cutting-edge technology that advances the field of TB genomics.” – Dr. Soumya Swaminathan, Chief Scientist, World Health Organization
  • AarogyaAI is a valuable partner for DR-TB control and elimination. It has supported us to strengthen our diagnostic capacity and quality, and to monitor and evaluate the impact of our interventions. AarogyaAI is a scalable and sustainable solution that contributes to the global fight against TB.” – Dr. Lucica Ditiu, Executive Director, Stop TB Partnership
4baseCare: A Precision Oncology Company for Personalized Cancer Care

How to get started with AarogyaAI?

If you are interested in using AarogyaAI for your diagnostic needs, you can request a demo on their website here. You can also contact them via email at info@aarogya.ai .You can also follow them on Facebook, LinkedIn to get the latest updates and news about their platform and products.

AarogyaAI is a healthtech startup that uses AI and genomics to diagnose drug resistance in a fast, accurate, and affordable way. It has developed a cloud-based SaaS platform that can analyse the DNA sequence of the pathogen and provide a comprehensive report of its drug susceptibility status within minutes. It can help the clinicians to make data-driven treatment decisions and prescribe the most effective and personalized therapy for the patient. It can also help the public health authorities to monitor and control the spread of drug resistance and design appropriate policies and interventions. AarogyaAI is a platform that makes diagnosis of drug resistance easy and accessible.

 

You May Also Like

More From Author

1 Comment

Add yours

+ Leave a Comment